FY2018 EPS Estimates for Agile Therapeutics, Inc. Reduced by Analyst (AGRX)
Agile Therapeutics, Inc. (NASDAQ:AGRX) – Stock analysts at William Blair dropped their FY2018 EPS estimates for Agile Therapeutics in a research report issued on Wednesday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.59) for the year, down from their previous estimate of ($0.09). William Blair also issued estimates for Agile Therapeutics’ FY2019 earnings at $0.31 EPS.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period in the previous year, the business earned ($0.29) earnings per share.
A number of other research analysts have also recently commented on AGRX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Agile Therapeutics in a report on Monday, October 2nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. ValuEngine cut Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price objective on shares of Agile Therapeutics in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $10.20.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its holdings in Agile Therapeutics by 39.2% in the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 780,578 shares during the last quarter. Royce & Associates LP lifted its holdings in Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after acquiring an additional 11,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after acquiring an additional 82,213 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Agile Therapeutics in the second quarter valued at approximately $309,000. Finally, LMR Partners LLP purchased a new stake in Agile Therapeutics in the second quarter valued at approximately $211,000. Hedge funds and other institutional investors own 67.59% of the company’s stock.
In other Agile Therapeutics news, Chairman Alfred Altomari acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.50% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.